Clinical Trials

95 enrolled

Recurrence, Lymphoma, B-Cell

NCT04673617 2026-04-03

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

45 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT07284433 2026-04-02

QUADvance

Phase 1/2 Recruiting

178 enrolled

Leukemia, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT07015242 2026-03-24

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Phase 2 Recruiting

65 enrolled

Lymphoma

NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

54 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT02601313 2026-03-18

ZUMA-2

105 enrolled 33 charts 3 FDA

Lymphoma, Mantle-Cell

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT06500273 2026-03-18

ALPHA3

Phase 2 Recruiting

250 enrolled

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT05624554 2026-03-16

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

300 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05537766 2026-03-10

ZUMA-25

19 enrolled 28 charts

Phase 1/2 Active not recruiting

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT04416984 2026-03-04

ALPHA2

160 enrolled

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04285567 2026-03-03

CRISTALLO

Phase 3 Completed

166 enrolled 27 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03939026 2026-03-02

ALPHA

Phase 1 Completed

50 enrolled

Lymphoma, Lymphoma, Follicular, Recurrence

NCT05714345 2026-03-02

EXPAND

2 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Recurrence

NCT05170828 2026-02-24

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Phase 1 Withdrawn

Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03666000 2026-02-02

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

135 enrolled

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03105336 2025-12-23

ZUMA-5

159 enrolled 27 charts 2 FDA

Phase 2 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06253663 2025-12-16

JKART-1

25 enrolled

359 enrolled 27 charts 1 FDA

Recurrence, Lymphoma, Mantle-Cell

NCT03391466 2025-12-01

ZUMA-7

Phase 3 Completed

Lymphoma, Large B-Cell, Diffuse

NCT06285422 2025-11-28

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

6 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04880434 2025-11-17

ZUMA-2

95 enrolled

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT04245839 2025-11-05

TRANSCEND FL

276 enrolled 5 FDA

Phase 3 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT05371093 2025-10-15

ZUMA-22

231 enrolled

Lymphoma, Follicular

NCT05878184 2025-10-02

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

16 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03860844 2025-09-09

ISAKIDS

67 enrolled 25 charts

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05950334 2025-08-22

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Phase 1 Completed

20 enrolled

Lymphoma, B-Cell

NCT05883449 2025-08-20

LuminICE-203

25 enrolled 21 charts

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT05653271 2025-08-11

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

42 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT07066397 2025-07-23

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

12 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05521087 2025-06-22

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Phase 1 Withdrawn

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04735471 2025-06-18

GLEAN-1

Phase 1 Terminated

34 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1/2 Recruiting

128 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT06092047 2025-05-16

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

Phase EARLY_PHASE1 Recruiting

10 enrolled

CD19-positive Relapsed or Refractory B-cell Malignancies

NCT05972720 2025-05-15

FIRCE-1

101 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06699771 2025-04-30

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

48 enrolled

Lymphoma, T-Cell

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2 Recruiting

248 enrolled

CNSLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

NCT05665062 2025-04-06

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

36 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04637763 2025-03-24

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

72 enrolled

Phase EARLY_PHASE1 Recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06532630 2025-02-28

Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies

9 enrolled

Phase 2 Active not recruiting

B-Cell Malignancy

NCT06093841 2025-02-11

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

46 enrolled

CNSLymphoidOther hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse

NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Phase 1/2 Terminated

38 enrolled 34 charts

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03761056 2024-12-04

ZUMA-12

42 enrolled 20 charts

Lymphoma, B-Cell

NCT02406092 2024-11-21

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Phase 3 Completed

139 enrolled 14 charts

Phase EARLY_PHASE1 Recruiting

Lymphoma, Non-Hodgkin

NCT06532643 2024-09-19

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

9 enrolled

Lymphoma

NCT03743246 2024-08-15

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Phase 1/2 Terminated

21 enrolled 33 charts

Immune System Diseases, Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02348216 2024-06-04

ZUMA-1

307 enrolled 41 charts

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06367114 2024-04-19

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

50 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06205290 2024-04-02

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Phase 3 Withdrawn

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02926833 2024-03-06

ZUMA-6

37 enrolled 28 charts